|
|
News Breaks | | | | June 21, 2012 | | 09:24 EDT |  | POZN | POZEN shares should be bought on weakness, says Roth Capital
After the FDA asked Pozen to provide additional information about its potentially less gastro-erosive aspirin, Roth Capital still believes that the company will be able to file an application for the drug with the FDA by the end of the year. The firm maintains a $10 target and Buy rating on the stock. | |
|
News For POZN From The Last 14 Days Check below for free stories on POZN the last two weeks. |
|
|
| May 8, 2013 | | 07:31 EDT |  | POZN | POZEN reports Q1 EPS (19c), consensus (19c)
 Subscribe for More Information | |
|
|
|
|
|
|
